ABH Optics Founders

ABH Optics Raises €1M to Pioneer World’s Thinnest Eyeglass Lenses

Copenhagen-based ABH Optics ApS, an innovative spin-off from the Technical University of Denmark (DTU), has successfully raised €1 million in a pre-seed funding round. The investment, led by High-Tech Gründerfonds (HTGF), positions the company to advance its groundbreaking work in developing the world’s thinnest and lightest eyeglass lenses. HTGF’s Senior Investment Manager, Olaf Joeressen, expressed…

Read More

Valerie Health Secures $30M Series A to Revolutionize AI-Powered Front Office for Independent Clinics

Valerie Health, the AI-driven front office for independent provider groups, has raised $30 million in a Series A round led by Redpoint Ventures, bringing its total funding to $39 million. The platform combines AI agents with human-in-the-loop oversight to automate administrative tasks such as referrals, faxes, and scheduling, significantly cutting operational costs while enhancing patient…

Read More

Ability Biologics Innovates AI-Driven Antibody Therapeutics with $18 Million Seed Funding Boost

Ability Biologics, a trailblazer in AI-driven therapeutic discovery, has closed an $18 million seed funding extension, marking a significant milestone in its quest to revolutionize antibody therapeutics for cancer and immune-related disorders. Led by founding investor Amplitude Ventures, this financing round includes strategic support from Fonds de solidarité FTQ, Investissement Québec, Charles River Laboratories, Theodorus,…

Read More

Ceres Imaging Transforms into CeresAI, Secures Series D Funding to Drive Innovation in AgTech

Ceres Imaging, the leading data and analytics provider for the agricultural sector, has rebranded as CeresAI, underscoring its commitment to advanced AI-driven solutions for agribusinesses and financial services. This strategic move highlights CeresAI’s decade-long expertise in computer vision and machine learning, aiming to revolutionize data accuracy and decision-making processes for large-scale farms, insurers, and lenders….

Read More

Rainforest Secures $20 Million Series A Funding to Revolutionize Embedded Payments

Rainforest, a trailblazer in embedded payment solutions for software platforms, announced today the successful closure of an oversubscribed $20 million Series A funding round led by Matrix Partners. This funding, which also saw participation from Accel, Infinity Ventures, BoxGroup, The Fintech Fund, Tech Square Ventures, and Ardent Venture Partners, builds on Rainforest’s previous seed round,…

Read More

3M Invests in Ohmium to Boost Green Hydrogen Production Technology

3M has solidified its commitment to advancing climate technologies with a strategic investment in Ohmium International, a pioneer in proton exchange membrane (PEM) electrolyzer systems for green hydrogen production. This investment underscores 3M’s proactive stance in supporting sustainable solutions aimed at fostering a low-carbon economy. Mark Copman, Senior Vice President of 3M New Growth Ventures,…

Read More

Marea Therapeutics Secures $190 Million to Propel Novel Cardiovascular Treatments

Marea Therapeutics has marked a significant milestone with the successful closure of a $190 million combined Series A and B financing, positioning the clinical-stage biotechnology firm to accelerate its pioneering efforts in cardiometabolic disease treatments. Led by Third Rock Ventures and supported by a consortium of leading investors including Sofinnova Investments, Forbion, and Perceptive Xontogeny…

Read More

Octane Secures $100M Series F to Accelerate Market Expansion and Technology Leadership

Octane, the fintech transforming the powersports and recreational vehicle purchasing experience, announced the successful closing of its Series F funding round, raising $100 million in equity capital. The latest infusion of capital will support the company’s growth initiatives, drive market penetration, and strengthen its technology platform, while also facilitating secondary share transfers. The round was…

Read More

Summit Therapeutics Raises $500 Million in Private Placement to Propel Ivonescimab’s Clinical Advancement and Solidify Leadership in Next-Gen Oncology

In a significant capital infusion, Summit Therapeutics Inc., a Miami-headquartered biopharmaceutical company specializing in oncology, has successfully raised $500 million through a private placement of approximately 26.68 million common shares priced at $18.74 each—the closing price on October 21, 2025. The offering was led by a blend of institutional biotech investors and company insiders, signaling…

Read More